This article is more than 5 years old. Information may no longer be current.

Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL

Issue: November/December 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting patients with newly diagnosed B-ALL predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or in second or greater relapse.